Prothena Corporation plc
NASDAQ:PRTABiotechnology
+$0.33 today
- Market cap
- $428.77M
- Beta
- -0.32
- P/E (TTM)
- -3.1
- EPS (TTM)
- -$2.81
Volume 0.76M
Average 0.51M
PRTA Operating Cash Flow
Cash generated by the company's core business operations during the period.
Prothena Corporation plcNASDAQ: PRTA
Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Operating cash flow turns positive
Q1 FY2026 operating cash flow was $28.88M, compared with -$53.36M a year earlier. Trailing-twelve-month operating cash flow was -$81.34M. Over 3 fiscal years it compounded at +14.6% a year.
Context
- Operating cash flow amounted to 1689.2% of revenue in FY2025, up 1578.2 pp from a year earlier.
- Operating cash flow grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly operating cash flow holds near $28.88M or moves back toward the trailing-twelve-month quarterly average of -$20.34M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (163.58M) USD
- Year-over-year change
- -9.0%
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (163.58M) | -9.0% |
| FY2024 | 2024-12-31 | (150.05M) | -12.1% |
| FY2023 | 2023-12-31 | (133.91M) | -23.1% |
| FY2022 | 2022-12-31 | (108.82M) | -217.5% |
| FY2021 | 2021-12-31 | 92.61M | — |
Operating Cash Flow vs competitors
How PRTA compares with its peers on the latest reported figures
- Peers report in different currencies, so operating cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -37.6% is the 9th highest of 10, against a peer median of +3.0%.
- Operating cash flow amounts to 140.4% of revenue for PRTA, versus a peer median of 1936.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $2.88B USD | +36.0% | +16.8% | 28.9% | |
| LTM Jun 2026 | $434.04M USD | +24.1% | +19.0% | 12043.3% | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $193.4M USD | -3.0% | +21.6% | — |
| LTM Mar 2026 | $183.1M USD | +31.0% | +17.0% | — | |
| LTM Mar 2026 | $105.55M USD | +3.0% | +48.7% | — | |
| LTM Mar 2026 | $81.34M USD | -37.6% | +14.6% | 140.4% | |
| LTM Dec 2025 | CHF 69.2M CHF | -205.1% | -3.5% | 1936.8% | |
| LTM Jun 2026 | $42M USD | +77.3% | +7.1% | — | |
| LTM Dec 2025 | $34.08M USD | -4.3% | +17.2% | — | |
| LTM Mar 2026 | $20.25M USD | -34.9% | +9.9% | — | |
| Peer median (excluding PRTA) | — | +3.0% | +17.0% | 1936.8% | |
Competitors are the stored peer set for PRTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 66.98M | (116.95M) | (147.03M) | (122.31M) | (244.09M) |
| Depreciation & Amortization | 1.12M | 744K | 928K | 893K | 895K |
| Deferred Income Tax | 4.57M | (11.13M) | (15.69M) | (9.35M) | 43.24M |
| Stock-Based Compensation | 24.66M | 31.32M | 40.91M | 45.96M | 37.64M |
| Change in Working Capital | (10.4M) | (18.8M) | (20.53M) | (67.94M) | (4.17M) |
| Accounts Receivables | 15K | 0 | (5.16M) | 5.16M | 0 |
| Inventory | 0 | 0 | (8.9M) | 0 | 0 |
| Accounts Payables | (492K) | 11.87M | 22.86M | (18.3M) | (15.78M) |
| Other Working Capital | (9.93M) | (30.67M) | (29.33M) | (54.8M) | 11.6M |
| Other Non-Cash Items | 5.69M | 6M | 7.5M | 2.69M | 2.91M |
| Operating Cash Flow | 92.61M | (108.82M) | (133.91M) | (150.05M) | (163.58M) |
| Capital Expenditures | (575K) | (464K) | (2.81M) | (298K) | (138K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 37K | 0 | 0 |
| Investing Cash Flow | (575K) | (464K) | (2.77M) | (298K) | (138K) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 174.79M | 223.62M | 23.58M | 0 | (139K) |
| Common Stock Repurchased | 0 | 0 | 0 | (353K) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 15.54M | 17.84M | 21.52M | 1.91M | 0 |
| Financing Cash Flow | 190.33M | 241.46M | 45.1M | 1.55M | (139K) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 282.36M | 132.17M | (91.58M) | (148.79M) | (163.86M) |
| Free Cash Flow | 92.03M | (109.29M) | (136.72M) | (150.35M) | (163.72M) |
Prothena Corporation plc
NASDAQ:PRTA
Intrinsic Alpha fair value
Locked
Current Price
$8.35
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.